Autoimmune thrombocytopenic purpura

Area of Science:

• Hematology
• Immunology
• Internal Medicine

Background:

• Autoimmune thrombocytopenic purpura (ATP) is a platelet disorder with genetic and female predispositions, often triggered by environmental factors like viral infections.
• It involves IgG antiplatelet antibodies that opsonize and lead to rapid destruction of platelets, primarily in the spleen.
• Increased megakaryocyte production and larger platelets (megathrombocytes) reflect heightened platelet turnover.

Purpose of the Study:

• To elucidate the mechanisms of platelet destruction in adult ATP.
• To evaluate the correlation between bound platelet IgG and disease severity.
• To understand the clinical presentation and therapeutic strategies for chronic ATP.

Main Methods:

• Analysis of IgG antiplatelet antibody production and its interaction with host platelets.
• Assessment of platelet destruction rates via the reticuloendothelial system.
• Evaluation of megakaryocyte and platelet morphology (megathrombocytes) and function.
• Review of treatment responses to steroids, splenectomy, and immunosuppressive therapy.

Main Results:

• Bound platelet IgG correlates with ATP severity, unlike serum antiplatelet IgG.
• Evidence suggests IgG binds directly to platelet antigens.
• Increased megakaryocyte mass and megathrombocytes indicate elevated platelet turnover and inversely correlate with platelet survival.
• Qualitative platelet functional defects associated with antiplatelet antibodies are common.

Conclusions:

• Adult ATP is typically a chronic condition requiring management focused on preventing purpura (platelet count > 40,000/cu mm).
• Steroids and splenectomy provide significant but not always permanent responses, with many patients remaining in a compensated thrombocytolytic state.
• Refractory cases pose therapeutic challenges, with immunosuppressive therapy offering limited efficacy and potential long-term risks.